Citrate/heparin/taurolidine - CorMedix Pharmaceuticals

Drug Profile

Citrate/heparin/taurolidine - CorMedix Pharmaceuticals

Alternative Names: Citrate/taurolidine/heparin; CRMD 003; CRMD 004; Heparin/citrate/taurolidine; Heparin/taurolidine/citrate; Neutrolin; Taurolidine/citrate/heparin; Taurolidine/heparin/citrate

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ND Partners
  • Developer CorMedix
  • Class Alkanesulfonic-acids; Antibacterials; Anticoagulants; Citrates; Heparins; Small molecules; Thiadiazines
  • Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease 1 stimulants; Factor Xa inhibitors; Heparanase inhibitors; Inflammation mediator inhibitors; Lipopolysaccharide inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Catheter infections

Highest Development Phases

  • Marketed Catheter infections

Most Recent Events

  • 25 Jul 2018 Interim adverse events data from the phase III LOCK-IT-100 trial in Catheter infections released by CorMedix
  • 15 May 2018 CorMedix anticipates completion of review and source-verification of data from the LOCK-IT 100 trial in Catheter infections (Prevention) by end of the second quarter of 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Catheter-infections(Prevention) in European Union (Gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top